TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Sponsor: Daiichi Sankyo · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 540 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT06203210 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06203210 Rescue Dossier →